Leading Covid-19 vaccine developer AstraZeneca agreed on Saturday to buy Boston pharmaceutical firm Alexion (ALXN) for $39 billion. The acquisition is one of the largest deals of the year for the ...

Alexion has routinely featured among lists of top biopharma takeover prospects in the last couple of years, and that was a good call – AstraZeneca has just swooped in with $39 billion cash-and ...

Alexion Pharmaceuticals, Inc. ALXN entered into a definitive agreement with U.K.-based pharmaceutical company, AstraZeneca plc AZN, whereby the latter will acquire the former. Per the terms ...

Britain’s AstraZeneca has agreed to buy U.S. drugmaker Alexion Pharmaceuticals for $39 billion in cash and shares to bolster its positions in immunology and rare diseases. AstraZeneca ...

AstraZeneca PLC AZN announced that the UK Competition and Markets Authority has allowed the company to close its impending merger with Alexion Pharmaceuticals, Inc. ALXN. The deal is expected to ...

Impact Link AstraZeneca ... will require US regulatory sign-off. Both boards unanimously approved the deal, which is expected to close in the third quarter of 2021. Alexion shareholders will ...

We’ll send you a myFT Daily Digest email rounding up the latest Mergers & Acquisitions news every morning. Anglo-Swedish drugmaker AstraZeneca has agreed to buy US biotechnology group Alexion in ...

The British company also said Sharon Barr, head of research and development at Alexion, would succeed Mene Pangalos, the long-time biopharmaceuticals head of research at AstraZeneca. Sign up here.

Monopar Therapeutics (NASDAQ:MNPR) rose around 20% ahead of trading on Thursday after it announced an agreement with Alexion, AstraZeneca Rare Disease, the group within AstraZeneca (NASDAQ ...

A little more than a year since its acquisition by AstraZeneca plc, Alexion Pharmaceuticals Inc. is operating in "the best of both worlds" as the official rare disease unit of the U.K. pharma giant.

read more Sign up here. The British company said on Saturday that Alexion shareholders would receive $60 in cash and about $115 worth of equity per share - either in AstraZeneca's UK-traded ...